PPCB · Propanc Biopharma, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Sep 25, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2023-07-05 | ZELINGER JOSEF |
Director |
Award↑
Filing footnotes — Common Stock Purchase Warrant (Indirect)
Due to an administrative error, the reporting person inadvertently failed to report the beneficial ownership of the common stock purchase warrant (the "Warrant") issued to Aggro Investments Pty Ltd ("Aggro Investments") on July 5, 2023. The Warrant is currently exercisable, with shares of Common Stock issuable upon exercise subject to a 4.99% blocker based upon the aggregate number of shares of Common Stock outstanding on the date of such exercise. The reporting person wholly owns and controls Aggro Investments, but disclaims beneficial ownership of the Warrant and shares issuable pursuant to its exercise, except to the extent of the reporting person's pecuniary interest therein. Reflects the receipt of the Warrant for no additional consideration in connection with a loan from Aggro Investments to the issuer on July 5, 2023. |
Common Stock Purchase Warrant
(I)
|
15,000,000 |
| 2021-08-17 | Kenyon Julian Norman |
Director, Chief Scientific Officer |
Award↑
|
Common stock, par value $0.001
|
3,420,000 |
| 2021-08-17 | Nathanielsz James Andrew |
Director, CEO/CFO |
Award↑
|
Common stock, par value $0.001
(I)
|
2,800,000 |
| 2021-08-17 | Nathanielsz James Andrew |
Director, CEO/CFO |
Award↑
|
Common stock, par value $0.001
(I)
|
5,928,000 |